Case Studies

Founded in August 2021 by SV Health Investors with SV Venture Partner and repeat entrepreneur, David Guyer, M.D., and Tony Adamis, M.D, EyeBio Limited (“EyeBio”) is a biotechnology company developing next-generation therapeutics for major eye diseases including diabetic macular edema (DME) and age-related macular degeneration (AMD), two leading causes of vision loss globally.

Oxford Space Systems (OSS) is a leading UK space‑technology company that specialises in the design and manufacture of advanced deployable antennas and structures for satellites.

Founded in 2019 by Dr Saahil Mehta, a Consultant Plastic Surgeon, Plexāā is a UK medtech company pioneering a new approach to surgical preparation.

The Dementia Discovery Fund (DDF) was launched in 2015 to invest exclusively in pioneering research and drug development to tackle neurodegenerative diseases, incl. Alzheimer’s, one of the largest unmet medical needs with over 55m patients worldwide and nearly 10m new cases every year.

Founded in 2016 by Ian Flanagan, a former professional tennis player turned entrepreneur, Voly Group is a leading yacht and multi-asset financial management platform.

OrganOx is at the forefront of changing the way donor organs are preserved in the critical time between donation and transplantation. OrganOx accessed venture capital via the Enterprise Capital Funds (ECF) programme, which it used to fund the clinical studies to secure market approval for its product, a complex class III medical device.

Tom Parker Creamery secured a £750,000 equity Investment from the South West Investment Fund enabling them to relocate to a larger facility and increase production capacity

Autonomous Drone Operations for Critical Infrastructure Pioneering UK Tech Firm Attracted Major Investment

A Leeds-based company whose technology could replace dashboard controls in cars and transform the way we operate appliances raised a further £3m to help prepare for mass production.

PEAK:AIO, a Manchester-based software company building ultra-fast storage systems for AI workloads has received a £5 million funding round.

Founded in 2019, Quell Therapeutics is a leader in engineered T-regulatory (Treg) cell therapies for medical conditions driven by abnormal immune responses.

Middlesbrough-based The Qualis Collection Ltd secured a six-figure investment from NPIF II – NEL Smaller Loans, which is managed by NEL Fund Managers as part of the Northern Powerhouse Investment Fund II (NPIF II).

Tokamak Energy is developing fusion energy technology, which is set to provide a limitless, clean energy source.

Business energy consultants Troo, based in Sunderland, secured a seven-figure investment from NPIF II – NEL Debt Finance, which is managed by NEL Fund Managers as part of the Northern Powerhouse Investment Fund II (NPIF II). The funding will enable the next phase of growth through cutting-edge technology and talent development.

Launched in 2013, Cambridge Innovation Capital (CIC) invests in deep-tech and life sciences businesses that have a connection with the Cambridge ecosystem.

Manchester Startup Finds Sweet Spot in Global Insurance Market. Veridox, an AI-powered fraud detection platform, has secured £1,000,000 in funding led by Outward VC, an early stage venture capital fund backed by the Enterprise Capital Funds programme.

Magnitude Biosciences, a specialist contract research organisation (CRO) in County Durham offering in vivo discovery of treatments for age-related conditions and other diseases using C. elegans, secured over £706,000 in combined funding to scale up its high-throughput screening (HTS) platform

David Newman is Founder and CEO of Firenze, a Manchester-based fintech on a mission to democratise access to Lombard lending - an investment-backed credit product traditionally reserved for high-net-worth individuals, backed by Outward VC through the British Business Bank’s Enterprise Capital Funds (ECF) programme.